The CSL Ltd (ASX: CSL) share price has been under pressure for most of the past two years, and investors are now asking a big question: Is this one of those rare moments when a top-tier blue chip becomes a genuine long-term bargain?
At yesterday's market close, CSL shares finished the day trading near $180, a level not seen in almost 7 years. And if it's any consolidation, this is far below where many analysts believe the company's share price should be.
Image source: Getty Images
What pushed CSL shares this low?
CSL's tough run began with softer profit guidance, rising operating costs and a slower-than-expected recovery in its plasma collections business. Combined with currency impacts and several earnings updates that fell short of expectations, investor sentiment gradually began to fade.
The company also rolled out a $500 million cost-cutting plan, which some investors saw as a sign that costs had gone too high. All of this has contributed to CSL moving from a market favourite to what many now see as one of the more oversold large caps on the ASX.
So, has the market gone too far?
Despite the share price slump, the underlying business is far from broken. Plasma collections have been improving, Seqirus (CSL's vaccines business) continues to perform well, and CSL Vifor is finally starting to settle after a challenging integration period.
Several analysts recently highlighted CSL as one of the highest-quality ASX 200 companies now trading at a multi-year discount. Some even described it as massively oversold, noting that the company's long-term growth drivers remain solid.
Recent broker targets reflect that view as well, with valuations sitting between $260 and $310, which is well above today's share price.
CSL still expects steady revenue growth over the medium term, improving margins as plasma collections return to normal, and continued strong demand for its immunoglobulin and vaccine products. With the company's long history of growth, solid balance sheet and global reach, the current share price is getting harder for many investors to look past.
What could shift investor sentiment?
A few things could help shift sentiment, including stronger FY26 guidance, better plasma collection volumes, steady progress with CSL Vifor, and clearer signs of growth in its key treatment areas. If CSL can deliver on these areas, it may be enough to help the share price move higher.
Foolish takeaway
For long-term investors, moments like this don't come around often. CSL is still one of Australia's most successful companies, with decades of growth behind it and a solid runway ahead.
Only time will tell whether the current CSL share price proves to be a generational buying level. But with the company's long record of growth and early signs of momentum returning, CSL is starting to look like one of the more attractive opportunities on the ASX.
